Gsk Plc (GSK.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2010 | 12-2009 | 12-2008 | 12-2007 | 12-2006 | |
| Sales | 28,392,000 | 28,368,000 | 24,352,000 | 22,738,650 | 23,217,530 |
| Cost of Goods | 7,592,000 | 7,380,000 | 6,415,000 | 5,210,920 | 5,008,653 |
| Gross Profit | 20,800,000 | 20,988,000 | 17,937,000 | 17,527,730 | 18,208,877 |
| Operating Expenses | 17,017,000 | 12,563,000 | 10,796,000 | 9,327,112 | 10,403,687 |
| Operating Income | 3,783,000 | 8,425,000 | 7,141,000 | 8,200,618 | 7,805,190 |
| Interest Expense | 831,000 | 783,000 | 843,000 | N/A | N/A |
| Other Income | 205,000 | 249,000 | 361,000 | -664,097 | -8,677 |
| Pre-tax Income | 3,157,000 | 7,891,000 | 6,659,000 | 7,536,521 | 7,796,513 |
| Income Tax | 1,304,000 | 2,222,000 | 1,947,000 | 2,221,221 | 2,300,418 |
| Net Income Continuous | 1,853,000 | 5,669,000 | 4,822,000 | 5,218,988 | 5,387,378 |
| Minority Interests | -219,000 | -138,000 | -110,000 | -96,312 | -108,717 |
| Net Income | $1,634,000 | $5,531,000 | $4,712,000 | $5,218,988 | $5,387,378 |
| EPS Basic Total Ops | 0.40 | 1.36 | 1.11 | 1.18 | 1.19 |
| EPS Basic Continuous Ops | 0.40 | 1.36 | 1.11 | 1.18 | 1.19 |
| EPS Diluted Total Ops | 0.40 | 1.35 | 1.10 | 1.18 | 1.18 |
| EPS Diluted Continuous Ops | 0.40 | 1.35 | 1.10 | 1.18 | 1.18 |
| EBITDA(a) | $5,667,000 | $10,236,000 | $8,733,000 | $9,223,741 | $8,763,229 |